Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.

Gadde KM, Parker CB, Maner LG, Wagner HR 2nd, Logue EJ, Drezner MK, Krishnan KR.

Obes Res. 2001 Sep;9(9):544-51.

2.

Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis.

Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ.

Hum Reprod Update. 2009 Jan-Feb;15(1):57-68. doi: 10.1093/humupd/dmn043. Epub 2008 Oct 15. Review.

PMID:
18927072
3.

Pharmacotherapy for obesity.

Ioannides-Demos LL, Proietto J, McNeil JJ.

Drugs. 2005;65(10):1391-418. Review.

PMID:
15977970
4.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
5.

Naltrexone/bupropion: an investigational combination for weight loss and maintenance.

Makowski CT, Gwinn KM, Hurren KM.

Obes Facts. 2011;4(6):489-94. doi: 10.1159/000335352. Epub 2011 Dec 15. Review.

6.

Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.

Padwal R.

Curr Opin Investig Drugs. 2009 Oct;10(10):1117-25. Review.

PMID:
19777400
7.

Combination therapy with naltrexone and bupropion for obesity.

Billes SK, Greenway FL.

Expert Opin Pharmacother. 2011 Aug;12(11):1813-26. doi: 10.1517/14656566.2011.591382. Epub 2011 Jun 21. Review.

PMID:
21689063
8.

ACS chemical neuroscience molecule spotlight on contrave.

Mercer SL.

ACS Chem Neurosci. 2011 Sep 21;2(9):484-6. doi: 10.1021/cn200076y. Review.

9.

Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone (DHEA).

MacEwen EG, Kurzman ID.

J Nutr. 1991 Nov;121(11 Suppl):S51-5. Review.

PMID:
1834816
10.

Naltrexone ER/Bupropion ER: A Review in Obesity Management.

Greig SL, Keating GM.

Drugs. 2015 Jul;75(11):1269-80. doi: 10.1007/s40265-015-0427-5. Review.

PMID:
26105116
11.

Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.

Apovian CM.

Future Cardiol. 2016 Mar;12(2):129-38. doi: 10.2217/fca.15.79. Epub 2015 Dec 18. Review.

PMID:
26679384
12.

Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs.

Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC.

Obes Rev. 2013 May;14(5):383-92. doi: 10.1111/obr.12015. Epub 2013 Jan 21. Review.

PMID:
23331711
13.

Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.

Verpeut JL, Bello NT.

Expert Opin Drug Saf. 2014 Jun;13(6):831-41. doi: 10.1517/14740338.2014.909405. Epub 2014 Apr 28. Review.

PMID:
24766397
14.

Clinical studies with the beta-adrenoceptor agonist BRL 26830A.

Connacher AA, Bennet WM, Jung RT.

Am J Clin Nutr. 1992 Jan;55(1 Suppl):258S-261S. Review.

PMID:
1345890
15.

Phentermine/topiramate for the treatment of obesity.

Smith SM, Meyer M, Trinkley KE.

Ann Pharmacother. 2013 Mar;47(3):340-9. Review.

PMID:
23482732
16.

The use of pharmacologic agents in the treatment of the obese patient.

Apovian CM.

J Am Osteopath Assoc. 1999 Oct;99(10 Su Pt 2):S2-7. Review.

PMID:
10624371
17.

Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?

Katsiki N, Hatzitolios AI, Mikhailidis DP.

Ann Med. 2011 Jun;43(4):249-58. doi: 10.3109/07853890.2010.541490. Epub 2011 Jan 24. Review.

PMID:
21254901
18.

The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update.

Christou GA, Kiortsis DN.

Hormones (Athens). 2015 Jul-Sep;14(3):370-5. doi: 10.14310/horm.2002.1600. Review.

19.

Recent advances in the pathophysiology and pharmacological treatment of obesity.

Chugh PK, Sharma S.

J Clin Pharm Ther. 2012 Oct;37(5):525-35. doi: 10.1111/j.1365-2710.2012.01347.x. Epub 2012 Mar 30. Review.

PMID:
22462645
20.

Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.

Ali KF, Shukla AP, Aronne LJ.

Expert Rev Clin Pharmacol. 2016;9(1):27-34. doi: 10.1586/17512433.2016.1100072. Epub 2015 Oct 29. Review.

PMID:
26512740

Supplemental Content

Support Center